Geron Corporation (NASDAQ:GERN) said the US Food and Drug Administration ordered a halt to trials of a cancer drug over concerns about potential liver damage. Geron Corporation (NASDAQ:GERN) stock performance was -61.59% in last session and finished the day at $1.69. Traded volume was 46,444,384 million shares in the last session and the average volume of the stock remained 4.64 million shares. The beta of the stock remained 1.67. Geron Corporation (NASDAQ:GERN) insider ownership is 0.10%.

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares traded down 14.6% on Wednesday following a dissappointing earnings announcement, American Banking & Market News reports. The stock traded as low as $4.34 and last traded at $4.51, with a volume of 6,310,404 shares. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) dropped -13.83 percent to $4.55 yesterday on volume of 7.36 million shares. The intra-day range of the stock was $4.34 to $4.70. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) has a market capitalization of $387.81 million.

Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shares plummeted nearly 14 percent in the current trading session after Oppenheimer slashed its ratings for the company from “Outperform” to “Market Perform” in a research note published on March 12. Northwest Biotherapeutics, Inc (NASDAQ:NWBO)’s stock on Mar 12, 2014 reported a decrease of -12.96% to the closing price of $7.99. Its fifty two weeks range is $3.10 -$10.64. The total market capitalization recorded $346.79 million. The overall volume in the last trading session was 3,711,925 million shares. In its share capital, Northwest Biotherapeutics, Inc (NASDAQ:NWBO) has 35.28 million outstanding shares.

Aeterna Zentaris Inc. (USA) (NASDAQ:AEZS) will announce its fourth quarter and full-year 2013 financial and operating results after market close on Thursday, March 20, 2014. The Company will host a conference call to discuss these results on Friday, March 21, 2014, at 8:30 a.m., Eastern Time. On Wednesday, shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) dropped -7.38% to close the day at $1.38. Company return on investment (ROI) is 403.00% and its monthly performance is recorded as 4.55%. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) quarterly revenue growth is 27.78%.